logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Roberto Crea

This inventor holds 10 USPTO granted patents. Top assignees: Creative Biomolecules, Inc., Genentech, Inc., A. Menarini S.a.s.. Active years: 1982-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roberto Crea. Retrieved from https://idiyas.com/inventor/roberto-crea-tgci8fa3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 308(Granted Patents)


Location History:

  • Burlingame, CA (US) (1982 - 1995)
  • Bulingame, CA (US) (1988 - 1997)
  • Boston, MA (US) (1991 - 2006)

Company Filing History:

goldMedal6 out of 72 
 
Creative Biomolecules, Inc.
 patents
silverMedal3 out of 3,304 
 
Genentech, Inc.
 patents
bronzeMedal1 out of 14 
 
A. Menarini S.a.s.
 patents
4. 1 out of 25 
 
Micromet Ag
 patents
where one patent can have more than one assignee

Years Active: 1982-2006

Loading Chart...
10 patents (USPTO):Explore Patents
1. 7105638 - Product and process for the production, isolation, and purification of recombinant polypeptide (2006-09-12),
2. 5700677 - Protein analogues of tissue plasminogen activator (1997-12-23),
3. 5460811 - Mature human fibroblast interferon (1995-10-24),
4. 5416007 - Enhanced proteolytic cleavage of recombinant fusion proteins (1995-05-16),
5. 5013653 - Product and process for introduction of a hinge region into a fusion (1991-05-07),
6. 5004686 - Process for producing human epidermal growth factor and analogs thereof (1991-04-02),
7. 4888286 - Production of gene and protein analogs through synthetic gene design (1989-12-19),
8. 4743679 - Process for producing human epidermal growth factor and analogs thereof (1988-05-10),
9. 4393010 - Nucleosidic phosphorylating agent and methods (1983-07-12),
10. 4310662 - Nucleosidic phosphorylating agent and methods (1982-01-12),

Title: The Innovative Contributions of Roberto Crea

Introduction

Roberto Crea is a prominent inventor based in Boston, MA, known for his significant contributions to the field of biotechnology. With a total of 10 patents to his name, Crea has made remarkable advancements in the production and purification of recombinant polypeptides, as well as the development of protein analogues.

Latest Patents

Crea's latest patents include a method for the production, isolation, and purification of recombinant polypeptides. This innovative method involves creating a fused polypeptide that contains a desired polypeptide linked to additional amino acids, which facilitate purification. The process is designed to efficiently isolate the polypeptide by exploiting the properties of the leader sequence and cleaving it in an appropriate aqueous environment. Another notable patent describes protein analogues of tissue plasminogen activator (tPA). These analogues maintain the proteolytic function of natural tPA while being of lower molecular weight, allowing for efficient expression in prokaryotic host cell systems.

Career Highlights

Throughout his career, Crea has worked with several notable companies, including Creative Biomolecules, Inc. and Genentech, Inc. His work has significantly impacted the biotechnology industry, particularly in the areas of protein engineering and therapeutic development.

Collaborations

Crea has collaborated with esteemed colleagues such as Charles M Cohen and Marc F Charette, contributing to various projects that have advanced the field of biotechnology.

Conclusion

Roberto Crea's innovative work and patents have made a lasting impact on biotechnology, showcasing his expertise and dedication to advancing scientific knowledge. His contributions continue to influence the development of new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…